Results 161 to 170 of about 176,276 (303)

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

open access: yesMolecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller   +10 more
wiley   +1 more source

Resisting resistance [PDF]

open access: yesNature Reviews Microbiology, 2012
openaire   +1 more source

Spatial and single‐nuclei transcriptomics reveals idiosyncratic and generic patterns in papillary and anaplastic thyroid cancers

open access: yesMolecular Oncology, EarlyView.
Matched spatial transcriptomics and single‐nuclei RNA‐seq were generated for anaplastic and BRAFV600E papillary thyroid cancers revealing generic and tumor‐specific states occurring in cancer cells and in the tumor microenvironment. In this context, cancer dedifferentiation mirrored organoid maturation through ordered thyroid marker gain/loss ...
Adrien Tourneur   +11 more
wiley   +1 more source

PRELIMINARY RESULTS OF WIDE-BAND MAGNETOTELLURIC SOUNDING IN SENYA-FAULT AREA, NORTHEASTERN JAPAN

open access: yes, 1999
1998年に地殻比抵抗研究グループは, 東北地方脊梁山地を横切る測線上で広帯域MT観測を行い, 下部地殻に至る比抵抗構造を解明した。横手盆地から花巻に至る東西45kmの測線上に, 15点の測点を配置した。この測線は, 西部では千屋断層を, 東部では北上低地西縁断層帯を横切る。2次元解析の結果, 千屋断層の破砕帯と思われる低比抵抗異常が深度7ー8kmまで続いていること, 北上低地西縁断層についても深度5ー6kmまで傾斜する低比抵抗異常がみられることがわかった。また地殻深部には ...
地殻比抵抗研究グループ
core  

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

open access: yesMolecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington   +10 more
wiley   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

open access: yesMolecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy